dysfunction; immune reconstitution; mesenchymal stem cells Hematopoietic stem cell transplantation (HSCT) has been a successful modality of treatment for children with a wide range of disorders for almost 40 years. HLA identical family donors can be found in up to 30% of recipients. The chance of finding a fully HLA identical, matched unrelated donor from the worldwide donor registry depends upon the recipients' ethnic background. Up to 70% of recipients of Caucasian origin will be successfully matched, but this may be as low as 10% in those of non-Caucasian backgrounds. 1 The inclusion of one-locus mis-matched donors (or two locus mis-matched cord blood) has further increased the chance of finding a suitable donor. 2, 3 In order to procure such a donor considerable time, money and effort is required. Despite these advances, a significant number of children requiring HSCT do not have a suitable donor. For those children requiring urgent HSCT, the time delay may preclude a successful outcome. As such, the advent of techniques to facilitate parents as donors has realized the potential that for every child there is a readily available donor. Early experience was associated with the frequent occurrence of graft versus host disease (GvHD), both acute and chronic, graft rejection and delayed immune reconstitution. 4 Aversa et al 5 proved that, in the haplo-setting, rejection and GvHD risk could be reduced by supplementing markedly T-cell depleted bone marrow with G-CSF mobilized, T-cell depleted peripheral blood stem cells. The mega-dose concept was described by Handgretinger et al 6 utilizing magnetic cell sorting (CliniMACS s ) and positive selection methodology. The CD34 þ content of the graft was significantly enhanced and almost devoid of donor T cells prior to infusion. In their experience, graft dysfunction was statistically related to the total CD34 þ cell dose infused.
Although post transplant immune suppression such as CSA and Tacrolimus are unnecessary with intense T-cell depletion, a significant delay in immune reconstitution post haplo-identical peripheral blood stem cell transplantation (PBSCT) exposes the child to reactivation of infections longer than is evident after an HLA matched HSCT. 7, 8 In our patient population we have incurred a significant risk of graft dysfunction following haplo-identical PBSCT unrelated to the final dose of CD34 þ stem cells administered. In this article we present our center's experience in children undergoing haplo-identical PBSCT since 1998. years (median 8.5 years). Indication for transplant was malignancy (n ¼ 14, ALL: CR1 n ¼ 3; CR2 n ¼ 5; CR3 n ¼ 1; ANLL/2e ALL n ¼ 1; MDS n ¼ 2; MDS/ANLL n ¼ 1; CML n ¼ 1) and nonmalignant conditions (n ¼ 4). All children with acute leukemia were, at the time of transplantation, in morphological remission. All donors were parents, in 12 instances the father (one father donated twice) and for 10 transplants the mother. In four cases both parents donated.
HLA typing was carried out using standard serological methods for HLA A and B loci and high-resolution typing for HLA DR loci. Peripheral blood stem cells were mobilized using granulocyte colony stimulating factor (G-CSF Neupogen s Amgen) at a dose of 1.0 IU/kg for a minimum of 5 days. Stem cells were harvested using continuous flow centrifugation at day 5. In addition, day 6 harvests were carried out in order to reach a total CD34 cell dose of 10 Â (60 mg/kg/day, on days À5 and À4), and total body irradiation either in one or two fractions depending upon age (7-12 Gy). Conditioning for ANLL was identical other than etoposide was omitted. Busulfan i.v. (3.2 mg/kg/day, from days À9 to À6) together with cyclophosphamide (60 mg/kg/day, on days À4 and À5) and melphalan 140 mg/ m 2 on day -1 was administered to children with MDS.
Busulfan i.v. (3.2 mg/kg /day, from days À10 to À7) and cyclophosphamide (50 mg/kg/day, from day À5 to day À2) was standard conditioning in children with nonmalignant conditions. In patients with rejection or primary nonengraftment further attempt at transplant was undertaken using either OKT3 (from day À1 until day þ 18) 0.1 mg/kg (maximum dose 5 mg) or fludarabine (30 mg/day, day À5 to day À1) and campath IH (0.2 mg/day, day À5 to day À2).
Results
Sustained engraftment, defined as a persistent absolute neutrophils count 40.5 Â 10 9 /l, was observed in 13 patients at a median of 17.0 days (range 13-26). One of these patients required G-CSF support from day þ 24 despite a documented 100% donor chimerism, possibly in light of a concurrent adenoviral infection. He later underwent a stem cell boost from the same donor at day þ 58 and is presently undergoing follow-up to assess his response. Three grafts failed and seven others, although showing initial hematological recovery, rapidly lost their donor cells. Cell doses administered in those with a sustained engraftment (n ¼ 13) ranged from 6.5 to 31.0 Â In patients transplanted for malignancy (n ¼ 14), seven are presently alive albeit two of these are þ 2 months and it is too early to say whether they will remain disease free. Of the truly evaluable patients the overall disease-free survival is 42% (Figure 3 ) at a follow-up of 1.5-6 years. Three children who engrafted relapsed (21%). However, five children (35%) developed graft dysfunction of whom only one survived. Of the remaining four children, all but one had documented engraftment following further re-transplantation, but all died from infection.
Overall graft dysfunction occurred in 6/18 patients (33%). No acute or chronic GvHD was documented.
In long-term survivors, immune recovery was substantially delayed and no detectable T-cell recovery was evident until 5-6 months post transplant. Functional T and B cell recovery was not evident until considerably later. In contrast, signs of NK activity were detectable as early as 1-month post PBSCT. Reactivation of CMV was evident in two children post transplant and herpes zoster in one other child. A total of five patients developed adenovirus infection. In 4/5 this was following second attempt transplantation either with OKT3 or fludarabine/campath IH conditioning. One patient developed adenoviral reactivation (defined as a plasma DNA load 410 3 copies/ml) shortly after engraftment. He remains under antiviral treatment with no evident dissemination. One child developed immune mediated thrombocytopenia, intracranial hemorrhage and PCP following steroids and emergency splenectomy, 3 months after successful engraftment for a secondary leukemia. After 4 years, he remains well with no clinically apparent neurological problems and in complete remission. 
Discussion
Our results are comparable to the reported literature in relation to overall and disease-free survival, especially in pediatric patients with underlying hematological malignancies. 9, 10 The overall survival rates are especially encouraging considering that these children would have certainly died from their initial disease without the transplant procedure. The lack of an otherwise suitable donor was no impediment to HSCT. Although it is generally reported that the problems of engraftment have been overcome in haplo-identical PBSCT, all centers undertaking this procedure have occasional patients with a dysfunctional graft. [11] [12] [13] However, even though some failures may be explained by differences in immune suppression given pre-transplant and lower doses of CD34 þ cells infused, 14, 15 there is no doubt that not all patients receiving mega doses of CD34 þ cells are guaranteed engraftment. 16 Our relatively high levels of graft dysfunction cannot be explained by either low numbers of CD34 þ cells infused nor insufficient pre-transplant immune suppression. Despite the introduction of mega doses of stem cells, we are neither able to predict nor overcome graft dysfunction based purely upon the final CD34 þ cell count administered, as described by other authors. 6, 17 We routinely administer antithymocyte globulin (ATG) to all patients pre-haplo-identical transplant as standard therapy. Children with hematological conditions undergo standard myelo-ablative conditioning, inclusive of total body irradiation, albeit as single fraction rather than fractionated radiotherapy.
As graft dysfunction has reduced the success of our haplo-identical transplants, we consider this to be a higher risk procedure than perhaps other centers with less lethal graft failure. Second attempt grafts in our unit have been complicated by lethal infections, mainly adenovirus, despite documented engraftment. It is hoped that with the recent introduction of PCR-monitoring and pre-emptive treatment this, as well as other viral infections, may be controlled. However, in light of the poor immune recovery, especially specific T-cell function, the control of infection may yet prove difficult. 8, 11 We observed a substantial number of viral infections in our patient population, but they did not differ substantially from other T-cell depleted HSCTs. Delayed recovery of adaptive immunity results from the degree of HLA disparity, the low numbers of T cells infused in the graft, and the use of ATG, which may inhibit T-cell expansion. 12 Pediatric studies show that the median time to normal T and B cell numbers and proliferative responses was 7-8 months and our patients have similar reconstitution profiles. 8 Initial T-cell recovery is of oligoclonal memory T cells as a result of expansion of peripheral T cells from the graft. Later, at approximately 6 months, naı¨ve T cells are recognizable presumably resulting from donor precursor cells emigrating from the thymus. 12 In the pediatric setting, immune recovery may be more rapid than in adults haplo-identical PBSCT for underlying hematological malignancies. The DFS is 41% with a follow-up of 1.5-6 years. This is comparable to published data, but the high levels of rejection compounded the success of the procedure.
because of intact thymic function and because it is feasible to infuse higher doses of CD34 þ cells that enhance the recovery of naı¨ve T cells. 8 The relatively low numbers of serious infections occurring in our patients with a sustained graft reflects this observation, together with the documented rapid neutrophil recovery.
Conclusion
Haplo-identical stem cell transplantation using highly enriched CD34 þ cells is a feasible solution for those children requiring HSCT, who otherwise have no suitable donor. Technological advances have made transplantation across major HLA-antigen barriers possible without the induction of fatal GvHD. Delays in immune reconstitution, despite good myeloid engraftment, are significantly greater than in the HLA matched allogeneic transplant setting, but mirror immune-reconstitution in T-cell depleted bone marrow transplantations. Infections have been no worse than in those children undergoing mis-matched unrelated allogeneic transplantation.
In our experience, nonengraftment and rejection cannot always be prevented by mega-doses of CD34 þ stem cells. Attempts at re-transplanting children with graft dysfunction have resulted in significant morbidity and mortality.
Apart from relapse, graft dysfunction and delayed immune reconstitution remain significant barriers to the application of this treatment to many more children, which would overcome the considerable time delays and expense of complicated donor searches. New strategies are presently being employed in our unit to combat these problems, namely the role of co-transplantation of expanded donor mesenchymal stem cells. These pluripotent stem cells, known to support hematopoiesis, may have an as yet undetermined role in improving the clinical outcome of children undergoing haplo-identical PBSCT. 18 
